P/E ratio for Sanara MedTech (SMTI)
P/E ratio as of April 2024 (TTM): -30.7
According to Sanara MedTech's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -30.7238. At the end of 2022 the company had a P/E ratio of -45.5.
P/E ratio history for Sanara MedTech from 2001 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -45.5 | 66.29% |
| 2021 | -27.4 | -61.65% |
| 2020 | -71.3 | 475.96% |
| 2019 | -12.4 | 45.85% |
| 2018 | -8.49 | -124.53% |
| 2017 | 34.6 | -641.81% |
| 2016 | -6.39 | 7.04% |
| 2015 | -5.97 | 177.33% |
| 2014 | -2.15 | 0.35% |
| 2013 | -2.15 | 47.23% |
| 2012 | -1.46 | -2.49% |
| 2011 | -1.49 | -25.29% |
| 2010 | -2.00 | -90.91% |
| 2009 | -22.0 | -47.46% |
| 2008 | -41.9 | 28.53% |
| 2007 | -32.6 | 2376.11% |
| 2006 | -1.32 | -56.14% |
| 2005 | -3.00 | -54.34% |
| 2004 | -6.57 | |
| 2001 | -141 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 OPKO Health
OPK | -4.67 | -84.81% | 🇺🇸 USA |
 Onconova Therapeutics ONTX | -0.9953 | -96.76% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.